Vaxart, Inc. Forms 3, 4 and 5: Other
Statements of beneficial ownership filed with the SEC by officers, directors and 10% owners: 3 rows, 3 shown. Transaction codes are the SEC's. Shares and prices are split-adjusted; the as-filed figure is underneath.
- 2018-02-13: Reporting owner Tucker Sean; Form 4; Security Stock Optin (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2018-02-13: Reporting owner Tucker Sean; Form 4; Security Stock Optin (right to buy); Transaction A Grant, award or other acquisition pursuant to Rule 16b-3(d).
- 2006-11-14: Reporting owner LYNCH TIMOTHY P; Form 3; Security No securities beneficially owned.; Transaction Holding.
VXRT insiders transactions against the stock price
Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close
Logarithmic scale. Both lines share the same starting value for the selected range.
Markers: each transaction type positioned at that session's split-adjusted close. Tooltips retain the reported transaction price when available.
| Transaction date | Reporting owner | Form | Security | Transaction | Shares | Price | Price that day | Filing |
|---|---|---|---|---|---|---|---|---|
| 2018-02-13 | Tucker Sean Officer (Chief Scientific Officer) | 4 | Stock Optin (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +7,731 7,731 owned after | $12.98 exercise price | $9.02 | 2018-02-15 |
| 2018-02-13 | Tucker Sean Officer (Chief Scientific Officer) | 4 | Stock Optin (right to buy) Derivative · Direct | A Grant, award or other acquisition pursuant to Rule 16b-3(d) | +9,060 9,060 owned after | $4.07 exercise price | $9.02 | 2018-02-15 |
| 2006-11-14 holding as of filing | LYNCH TIMOTHY P Director | 3 | No securities beneficially owned. Non-derivative · Direct | Holding | 0 owned after | no price filed | 2006-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B |